Trevena’s AT1 receptor-selective agonist TRV027 Aimed at COVID-19 in Two Studies

Trevena AT1 TRV027
Published on :

Trevena Inc.’s novel AT1 receptor-selective agonist TRV027 will be included in an international, adaptive Phase II/III study as a potential treatment for COVID-19 patients. The study is being supported by multiple international governments and global research organizations.

GSK to support manufacture of Novavax’ COVID-19 vaccine

Published on :

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK Government Vaccines Taskforce announced that they have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May 2021, with a rapid technology transfer between the two companies beginning immediately. GSK and Novavax will negotiate a final agreement to include additional terms and conditions.

Novavax trials highlight Maryland’s COVID-fighting complex

Published on :

Novavax trials highlight Maryland’s COVID-fighting complex When Novavax Inc. received $1.6 billion last year from the federal government to speed up testing and production of a coronavirus vaccine, some observers [….]

AGT’s Same-Day RT-PCR COVID-19 Testing Program is Helping People Safely Return to the Workplace

Same-Day RT-PCR COVID-19 Testing
Published on :

AGT’s new COVID-19 testing capability provides less expensive, more convenient, and highly accurate same-day COVID-19 to its own staff and the general public. RT-PCR testing is the “Gold Standard” of COVID-19 tests; AGT’s testing program was designed to help its employees and other local organizations’ staff return to and remain safe in the workplace.

Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™

Published on :

Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™ GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021 — Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, [….]

Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine

Published on :

Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine Canadian government commits to purchase 52 million doses with option for additional 24 million of Novavax candidate vaccine, [….]